| Case |
Age |
Sex |
PFS
(months) |
OS
(months) |
Interval between Cmab and Pmab <120 days* |
Best overall response |
CTC count |
| 1 |
64 |
F |
0.4 |
1.7 |
Yes |
PD |
19 |
| 2 |
45 |
F |
2.3 |
4.3 |
Yes |
PD |
21 |
| 3 |
54 |
F |
3.0 |
6.4 |
Yes |
PD |
1 |
| 4 |
43 |
M |
4.5 |
17.6 |
Yes |
SD |
0 |
| 5 |
48 |
M |
1.0 |
1.9 |
Yes |
PD |
18 |
| 6 |
40 |
F |
3.0 |
4.9 |
Yes |
PD |
0 |
| 7 |
40 |
M |
1.8 |
3.2 |
Yes |
PD |
2 |
| 8 |
57 |
M |
0.5 |
2.2 |
No |
NE |
12 |
| 9 |
74 |
F |
5.3 |
10.7 |
No |
SD |
0 |
| 10 |
60 |
F |
3.6 |
7.1 |
No |
SD |
0 |
| 11 |
58 |
M |
3.5 |
11.2 |
Yes |
SD |
9 |
| 12 |
47 |
F |
2.1 |
5.2 |
Yes |
PD |
2 |
| 13 |
41 |
M |
2.0 |
3.5 |
Yes |
PD |
0 |
| 14 |
59 |
M |
4.6 |
12.8 |
No |
SD |
0 |
| 15 |
71 |
F |
1.4 |
4.8 |
Yes |
PD |
0 |
| 16 |
78 |
F |
0.7 |
10.3 |
Yes |
NE |
4 |
| 17 |
54 |
M |
1.4 |
3.1 |
Yes |
PD |
222 |
| 18 |
71 |
F |
4.1 |
6.7 |
Yes |
PD |
1 |
| 19 |
61 |
M |
2.6 |
9.0 |
Yes |
PD |
0 |
PFS=Progression-Free Survival; OS=Overall Survival; CTC=Circulating Tumor Cells; SD=Stable Disease;
PD=Progressive Disease; NE=Not Evaluable; Cmab=Cetuximab; Pmab=Panitumumab.
*Interval between last administration of cetuximab and first administration of panitumumab.
Blood sample for CTC count was taken on same day as administration of panitumumab.
|
